Hematologic Diseases

175 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Hematologic Diseases
Treatment and conditionWhere it standsTrials
AAV2/8-HLP-FVIII-V3 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AB-8939 for gata2 deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abatacept for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Albipagrastim alf for febrile neutropeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE + Melphalan for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
allogeneic hematopoietic stem cell transplantation + Pharmacological Study + CLOFARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ANB-010, dose 1 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ANB-010, dose 2 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ANB-010, dose 3 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Antithrombin iii human for antithrombin iii deficiencyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ascorbic Acid for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aspirin for purpura, thrombotic thrombocytopenicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ASTX727 for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for myelodysplastic syndromesTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
ATO + Ascorbic acid for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous testicular tissue transplantation of prepubertal frozen testicular tissue for hematologic diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine for thrombocytopeniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + Ascorbic Acid for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Azacitidine + Ascorbic Acid for myeloproliferative disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + ENASIDENIB MESYLATE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azacitidine + Venetoclax + Mobinitinib for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD3632 for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD3632 + Posaconazole for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benralizumab for hypereosinophilic syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benserazide Only Product for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benserazide Only Product for beta-thalassemiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bezuclastinib for myeloproliferative disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Bone Marrow Aspiration + Olaparib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 + Famotidine + PANTOPRAZOLE for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 + Placebo for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BPA prophylaxis + Factor (FVIII or FIX) prophylaxis + FITUSIRAN for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brentuximab vedotin for hematologic diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CID-103 for purpuraPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CIPROFLOXACIN + Ceftazidime for febrile neutropeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CliniMACS + G-CSF + HPC,A Infusion + RITUXIMAB + BLINATUMOMAB + Cyclophosphamide + THIOTEPA + LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN + Mesna + FLUDARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CliniMacs TCR alpha-beta-Biotin system for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Clotting factor concentrates (CFC) or bypassing agents (BPA) + EMICIZUMAB + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clotting factor concentrates (CFC) or bypassing agents (BPA) + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Crizanlizumab for anemia, sickle cellTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CSL222 (AAV5-hFIXco-Padua) for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CYTARABINE + Cladribine + Azacitidine + Venetoclax for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Danicopan for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Darbepoetin alfa + canakinumab for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Decitabine + ARSENIC TRIOXIDE for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Decitabine + QUIZARTINIB + Venetoclax for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
DIAG723 for telangiectasia, hereditary hemorrhagicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor Leukocyte Infusion (DLI) + INTERFERON GAMMA-1B for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor mobilized PBSC infusion + G-CSF + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor mobilized PBSC infusion + G-CSF + Total Body Irradiation (TBI) (Plan 1) + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EDIT-301 for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
efanesoctocog alfa (BIVV001) for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elritercept for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elritercept for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exagamglogene autotemcel for anemia, sickle cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)5
Exagamglogene autotemcel for beta-thalassemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Exerenibart for beta-thalassemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fidanacogene Elaparvovec for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Fidanacogene Elaparvovec for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Fitusiran for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Fitusiran for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Givinostat for primary myelofibrosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Givinostat for thrombocythemia, essentialTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GVHD prophylaxis regimen + RIC regimen for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GVHD prophylaxis regimen + RIC regimen for bone marrow failure disordersPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hematopoietic stem-cell transplantation for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
HMB-002 (Part A) for von willebrand disease, type 3Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HMB-002 (Part B) for von willebrand disease, type 3Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) for von willebrand disease, type 3Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxycarbamide for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iloprost for vaso-occlusive crisesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Imatinib Mesylate for hypereosinophilic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Immediate HSCT Group for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iron sucrose for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Isatuximab for anemia, aplasticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myeloproliferative disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myeloproliferative disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Luspatercept for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Luspatercept for myelodysplastic syndromesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Luspatercept for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Lusutrombopag combined with recombinant human thrombopoietin for thrombocytopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Marstacimab for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Marstacimab for hemophilia bPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mitapivat for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mobinitinib for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Momelotinib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Navitoclax for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nintedanib for telangiectasia, hereditary hemorrhagicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nk-dli for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peginterferon α-2b injection for thrombocythemia, essentialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pelabresib for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for thrombocytopeniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pozelimab + cemdisiran for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton Total Marrow Irradiation for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
RITUXIMAB + Cyclophosphamide + MP + Busulfan + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for cytopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Romiplostim for anemia, aplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Romiplostim for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ROPEGINTERFERON ALFA-2B for thrombocythemia, essentialPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rosuvastatin for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib + NAVITOCLAX for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxoprubart for hemoglobinuria, paroxysmalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Selinexor for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax for myelodysplastic-myeloproliferative diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Azacitidine for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Azacitidine for myelodysplastic-myeloproliferative diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic-myeloproliferative diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SPK-8011QQ for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SR604 for factor vii deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
SR604 for hemophilia aPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SR604 for hemophilia bPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SR604 for von willebrand diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Stem Cell Infusion + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + TREOSULFAN + FLUDARABINE + Tacrolimus for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tasquinimod for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TASQUINIMOD + Ruxolitinib for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
thrombopoietin receptor agonist (TPO-RA) + Cyclosporine + ROMIPLOSTIM for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Tranexamic acid for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for thrombocytopeniaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ULIXERTINIB + Ruxolitinib for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Venetoclax + AB-8939 for gata2 deficiencyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Venetoclax + FLUDARABINE for myelodysplastic syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vitamin C (ascorbic acid) for cytopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vitamin C (ascorbic acid) for myelodysplastic syndromesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Zemocimig for hemophilia aPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1